Dashboard
Manage Tickers

VRDN


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

reported-earlier-viridian-therapeutics-prices-25135m-public-offering-of-11425m-common-shares-at-22-per-share-to-fund-veligrotug-vrdn-003-commercial-launch-rd-activities-and-general-corporate-purposes
Reported Earlier, Viridian Therapeutics Pr...
10/22/2025 07:26:19

Viridian intends to use the proceeds from the proposed underwritten public offering of its shares of common stock, together wit...

viridian-therapeutics-launches-an-underwritten-public-offering-of-its-common-stock-and-series-b-non-voting-convertible-preferred-stock-financial-terms-not-disclosed
Viridian Therapeutics Launches An Underwri...
10/21/2025 20:03:23

Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing and commercializing poten...

expert-outlook-viridian-therapeutics-through-the-eyes-of-6-analysts
Expert Outlook: Viridian Therapeutics Thro...
10/21/2025 20:00:39

dri-healthcare-trust-acquires-royalty-interest-in-us-net-sales-of-veligrotug-from-viridian-therapeutics-for-aggregate-purchase-price-of-300m
DRI Healthcare Trust Acquires Royalty Inte...
10/20/2025 11:34:52

Core News & Articles
10 Health Care Stocks With Whale Alerts In...
09/29/2025 17:35:29

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and...

these-analysts-revise-their-forecasts-on-viridian-therapeutics-following-q2-results
These Analysts Revise Their Forecasts On V...
08/07/2025 18:37:46

goldman-sachs-maintains-buy-on-viridian-therapeutics-raises-price-target-to-30
Goldman Sachs Maintains Buy on Viridian Th...
08/07/2025 17:53:04

Goldman Sachs analyst Richard Law maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from ...

rbc-capital-maintains-outperform-on-viridian-therapeutics-lowers-price-target-to-41
RBC Capital Maintains Outperform on Viridi...
08/07/2025 15:34:16

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and lowers the price target ...

wells-fargo-maintains-equal-weight-on-viridian-therapeutics-lowers-price-target-to-26
Wells Fargo Maintains Equal-Weight on Viri...
08/07/2025 14:36:11

Wells Fargo analyst Derek Archila maintains Viridian Therapeutics (NASDAQ:VRDN) with a Equal-Weight and lowers the price tar...

oppenheimer-maintains-outperform-on-viridian-therapeutics-raises-price-target-to-32
Oppenheimer Maintains Outperform on Viridi...
08/07/2025 13:31:02

Oppenheimer analyst Leland Gershell maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price tar...

needham-maintains-buy-on-viridian-therapeutics-lowers-price-target-to-34
Needham Maintains Buy on Viridian Therapeu...
08/06/2025 18:07:34

Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price target from $36...

viridian-therapeutics-q2-eps-100-beats-102-estimate-sales-75000k-beat-43643k-estimate
Viridian Therapeutics Q2 EPS $(1.00) Beats...
08/06/2025 11:56:16

Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(1.00) per share which beat the analyst consensus estimate of...

viridian-therapeutics-signs-70m-upfront-licensing-deal-with-kissei-for-veligrotug-and-vrdn-003-iin-japan-with-up-to-315m-in-milestones
Viridian Therapeutics Signs $70M Upfront L...
07/30/2025 08:21:56

Kissei obtains an exclusive license to develop and commercialize veligrotug and VRDN-003 in Japan -Viridian to receive an upfro...

needham-reiterates-buy-on-viridian-therapeutics-maintains-36-price-target
Needham Reiterates Buy on Viridian Therape...
05/20/2025 15:23:44

Needham analyst Serge Belanger reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $36 price target.

viridian-therapeutics-announces-positive-long-term-durability-data-from-thrive-phase-3-clinical-trial-of-veligrotug-in-ted-patients
Viridian Therapeutics Announces Positive L...
05/20/2025 11:06:11

- 70% of patients treated with veligrotug in THRIVE who were proptosis responders at week 15 maintained their response at week ...

what-5-analyst-ratings-have-to-say-about-viridian-therapeutics
What 5 Analyst Ratings Have To Say About V...
05/07/2025 22:00:53

viridian-therapeutics-receives-fda-breakthrough-therapy-designation-for-veligrotug-for-thyroid-eye-disease
Viridian Therapeutics Receives FDA Breakth...
05/07/2025 20:16:29

- Breakthrough Therapy Designation request based on veligrotug's (i) consistent and robust improvement and resolution of di...

rbc-capital-maintains-outperform-on-viridian-therapeutics-lowers-price-target-to-45
RBC Capital Maintains Outperform on Viridi...
05/07/2025 17:50:09

RBC Capital analyst Michael Carroll maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and lowers the price tar...

goldman-sachs-maintains-buy-on-viridian-therapeutics-lowers-price-target-to-27
Goldman Sachs Maintains Buy on Viridian Th...
05/07/2025 17:11:48

Goldman Sachs analyst Richard Law maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price target from ...

jmp-securities-maintains-market-outperform-on-viridian-therapeutics-lowers-price-target-to-38
JMP Securities Maintains Market Outperform...
05/07/2025 16:44:45

JMP Securities analyst Jason Butler maintains Viridian Therapeutics (NASDAQ:VRDN) with a Market Outperform and lowers the pr...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION